A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. - Test2 - elhamkhani - TriplyDB

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.

http://www.wikidata.org/entity/Q33387547

about

Beyond taxanes: the next generation of microtubule-targeting agents Systematic review of ixabepilone for treating metastatic breast cancer.Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone Ixabepilone development across the breast cancer continuum: a paradigm shift.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.Combining emerging agents in advanced breast cancer Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NC Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy.Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone.Drug resistance and the role of combination chemotherapy in improving patient outcomes.Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?Global experience with ixabepilone in breast cancer.Ixabepilone for the treatment of breast cancer.Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?Platinum-based compounds for the treatment of metastatic breast cancer.What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.Silencing A7-nAChR levels increases the sensitivity of gastric cancer cells to ixabepilone treatment.Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients.

P2860

Q26865369-9C4744CE-7B3D-408F-BF78-10D4350F9907 Q30248627-6312A781-B598-4643-A385-147BF4D6FB20 Q33827808-6F4B824F-D5C4-4403-8528-97D3AF932329 Q34274930-2F8E9CA0-F2E1-4A13-803F-D96B3485E332 Q34417996-4B02708D-C939-4A35-86FA-8F0E9C363BF3 Q35018233-E0A0B5E9-B510-4FA7-BB02-12A825349818 Q35076330-06116111-15D8-4547-A8DC-1D82F801856F Q35584962-E21DAE64-35EE-48FF-B7F5-59D549A9F8DF Q35847455-CE908B71-6699-410C-8CBA-A1C15C4BCD32 Q35872691-6D2412AB-D425-4DE7-B5F2-A2BAA1E463BD Q35975007-78D5B0CB-3FDA-46EF-9DED-44B6FB9E0C09 Q36999509-20219B16-D1D0-4347-83F4-8EF2F26FA3E2 Q37355762-0EA02864-0D58-4D77-B1D5-58E96A09268E Q37799220-C3BF3675-CFD9-4CA4-96E9-A58C0D07FDC1 Q37873462-8C4A1ABC-3A51-4C98-84A4-CB06FED1B9B1 Q37876407-F9626186-058F-45FE-8DFD-599B45A87DFC Q37928232-6710D059-6B2F-4DA2-83D8-24FE61888768 Q37976172-54DBB7EC-9B4F-4BD5-8CAF-0374B05B41ED Q37982444-2FB195D4-49B6-4E43-9B75-560AA39E6CC5 Q38527538-EE5DBDBE-2BDF-4499-975D-ADED1493DBE6 Q53800820-3BC4DAC3-599D-412B-8A28-4F7021044092 Q54685246-51F69F43-2055-4E90-829D-E7740493465F

P2860

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial.

http://www.wikidata.org/entity/Q33387547

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@ast

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@en

type

label

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@ast

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@en

prefLabel

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@ast

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@en

P1433

Q33387547-EEB42533-FE0D-4DD5-B4FF-86735B205F4E

P1476

Q33387547-4BB00118-6BC3-476E-B446-37736DAEDD12

P2093

Q33387547-437465B6-879F-4BC6-9E3F-5AF0B7817CAD

Q33387547-7C107766-0A7D-4F8F-847D-E333953870E6

Q33387547-7DE83554-5ABE-47B6-B750-31139C1265E4

Q33387547-7FF287C4-DECD-41E3-BED4-19CE6D1BF52E

Q33387547-A7242A35-CCF7-46AC-9B58-E44E380A0326

Q33387547-C10F9033-6DD8-4271-9052-FEAFE1D4A98A

Q33387547-DEAD254A-5B92-4F35-97FC-8A968F9E18AD

Q33387547-E1642D14-5B97-471C-87F6-8A1B046D2D62

Q33387547-E9772603-639D-409B-8B1E-236B576EE2E4

P2860

Q33387547-040F27DD-892E-481D-B180-48BB23DC9C5B

Q33387547-17DBF556-C579-4F6A-828A-4903D17987E1

Q33387547-26CEE568-92FD-4CF8-9A96-F779A1D31C86

Q33387547-364B8DFC-B011-49E4-8BF6-6226DB2BBC7F

Q33387547-365806BC-501D-4987-B0F1-1DFB8C2CFC07

Q33387547-384BE5A2-69B9-4C6D-BD17-65AE0DD78E2E

Q33387547-481147B2-0864-4E02-A8B2-5F874B91A62C

Q33387547-6DD5D731-B3B7-47DE-AF88-0272E126A9C3

Q33387547-72D7BAFF-3297-4C51-8C49-2B939CB9F590

Q33387547-73A10802-90DC-4C75-8265-2F27E25DD086

P2888

Q33387547-C1BABA58-872D-495E-ABF9-B9F68529D02C

P304

Q33387547-46F700FC-11B4-47D9-883A-9D13416C6624

P31

Q33387547-401AD8A3-74D7-465A-B230-39606BE7D68A

P356

Q33387547-090F67B3-6DC6-4DEB-9BEA-44479B3BDEDB

P407

Q33387547-52B847A3-94FF-4B09-B078-E90162250AD3

P433

Q33387547-6CB43D32-A2EB-49DA-8CD2-8796FD2A5771

P478

Q33387547-41B1F7A4-30A3-4C70-A2D5-BF2C5C3D944C

P577

Q33387547-159D4D4B-B0D3-445A-BFFB-6AE661E4192F

P5875

Q33387547-CEC4256D-03E7-4F42-85B3-F5B7B7AF9E0A

P6179

Q33387547-F0D79F3D-5127-4EC6-A528-69CDC198D380

P698

Q33387547-B09E39DA-1B49-46DA-A8AE-AEE195674FE6

P921

Q33387547-BC0CD72E-80D0-4FED-9FF4-FAC013A37BCA

P932

Q33387547-10854DF4-D9C6-45DD-9296-3692E777258B

P356

S10549-009-0658-9

P1433

Breast Cancer Research and Treatment

P1476

A phase II trial of trastuzuma ...... perative Oncology Group Trial.

@en

P2093

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

George W Sledge

http://www.w3.org/2001/XMLSchema#string

Hailun Li

http://www.w3.org/2001/XMLSchema#string

Joseph A Sparano

http://www.w3.org/2001/XMLSchema#string

Michael Pins

http://www.w3.org/2001/XMLSchema#string

Molin Wang

http://www.w3.org/2001/XMLSchema#string

Stacy Moulder

http://www.w3.org/2001/XMLSchema#string

William J Gradishar

http://www.w3.org/2001/XMLSchema#string

Ximing Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.

Weekly paclitaxel in the adjuvant treatment of breast cancer.

Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind.

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography.

P2888

s10549-009-0658-9

P304

663-671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-009-0658-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2010-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40689788

http://www.w3.org/2001/XMLSchema#string

P6179

1015029255

http://www.w3.org/2001/XMLSchema#string

P698

20012354

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3133687

http://www.w3.org/2001/XMLSchema#string